Regulatory HHS appoints permanent FDA CBER, CDER heads Pharmaceutical TechnologyThe HHS appoints these leadership positions as it looks to "reform" the FDA, which has recently faced a high turnover in leadership.Read full story pharminent September 10, 2026 (Last updated: September 10, 2026) Pharmaceutical Technology The HHS appoints these leadership positions as it looks to “reform” the FDA, which has recently faced a high turnover in leadership. Read full story Post navigation Previous: Solstice Oncology secures $225m to drive porustobart’s development for cancerNext: Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026